Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SOMERSET SELEGILINE SUIT v. FDA HEARING SET FOR SEPT. 4; IN VIVO CONFIDENCE INTERVALS MAY DIFFER BETWEEN ELDEPRYL AND GENERICS FROM ENDO, NOVOPHARM, LEDERLE

Executive Summary

Somerset Pharmaceuticals is seeking to a preliminary injunction against FDA relating to the Aug. 2 approvals of three ANDAs for 5 mg tablets of the adjunctive Parkinson's disease treatment selegiline from DuPont Merck's Endo Labs, Novopharm and Lederle.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028693

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel